Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Targeting multiple myeloma antigens

Rakesh Popat • 14 Jun 2019
EHA 2019
Multiple Myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses target antigens in multiple myeloma, namely CD38 and BCMA, and the rationale behind their therapeutic targeting.This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals